Abstract 249P
Background
Abnormal uterine bleeding is the most common complaint in women attending to physicians, especially in the peri-menopausal and post-menopausal period which is reported to account for 70% of all gynecological consultations. The main aim of investigations for abnormal uterine bleeding is to rule out intrauterine pathology, particularly endometrial cancer or atypical hyperplasia.The study was aimed to conduct a systematic review and meta-analysis to evaluate the diagnostic accuracy of endometrial biopsy with Pipelle in women with abnormal uterine bleeding compared to D&C (reference standard) and sufficiency of the obtained endometrial tissue of two techniques.
Methods
Literature for studies published between 1965 and 2019 comparing the results of Pipelle with findings by D&C was searched. The QUADAS 2 tool was performed to evaluate the risk and applicability of each study. The diagnostic accuracy of Pipelle was evaluated through calculation of sensitivity, specificity, positive likelihood ratio, negative likelihood ratio and diagnostic odds ratio with pooled proportion.
Results
A total of 8 studies and 1675 patients were included in this meta-analysis. The pooled sensitivity of endometrial sampling by Pipelle was 70.9% (95%CI: 58.1%-81.1%) in endometrial tumor, 97.2% (95%CI: 95.5%-98.3%) in endometrial benign disease, and 94.4% (95%CI 92.7%-95.8%) in normal endometrium. The pooled specificity of Pipelle was 99.6% (95%CI: 99.0%-99.9%) in endometrial tumor, 74.7% (95% 56.4%-87.1%) in endometrial benign disease, and 90.0% (95%CI 75.5%-96.3%) in normal endometrium. The positive likelihood ratio by Pipelle in the diagnosis of endometrial tumor, benign disease and normal endometrium was 191.06 (95%CI 70.81-515.48), 28.86 (95%CI 15.10-55.19) and 9.573 (95%CI 4.28-21.40), while the negative likelihood ratio by Pipelle was 0.337 (95%CI 0.236-0.482), 0.241 (95%CI 0.131-0.444) and 0.07 (95%CI 0.04-0.11), respectively. The highest DOR 851.68 was achieved in the result of endometrial tumor.
Conclusions
Pipelle can be introduced as a suitable alternative of diagnostic curettage. When an adequate specimen is obtained, a positive test result is more accurate for ruling in disease than a negative test result for ruling it out.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
51P - Enhancing the anti-breast tumour activity of STING through a novel sting transcriptional regulator
Presenter: Hanchu Xiong
Session: Poster display session
Resources:
Abstract
52P - Reverse Warburg effect-related mitochondrial activity and 18F-FDG uptake in invasive ductal carcinoma
Presenter: Byung Wook Choi
Session: Poster display session
Resources:
Abstract
53P - Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma (ART): Final analysis report
Presenter: Abdullah Altwairgi
Session: Poster display session
Resources:
Abstract
54P - Association between Parkinson’s disease and brain tumours: A nationwide population-based cohort study
Presenter: Joo-hyun Park
Session: Poster display session
Resources:
Abstract
55P - Toxicity profiles of treatment with modern fractionated radiotherapy, contemporary stereotactic radiosurgery, or transsphenoidal surgery in non-functioning pituitary macroadenoma
Presenter: Kevin Sheng-Po Yuan
Session: Poster display session
Resources:
Abstract
56P - Hippocampal avoidance in WBRT for metastases: Comparative neurocognitive and dosimetric assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
57P - Multidisciplinary brain metastasis clinic: Is it effective and worthwhile?
Presenter: Annu Rajpurohit
Session: Poster display session
Resources:
Abstract
58P - Functional status as a determinant prognostic factor for overall survival in adult patients with medulloblastoma treated with chemotherapy and radiotherapy
Presenter: Juan Ayala Alvarez
Session: Poster display session
Resources:
Abstract
59P - Pattern of care in high-grade gliomas after recurrence
Presenter: Nandini Menon
Session: Poster display session
Resources:
Abstract
60P - Five fractions plus “SRS” boost combined with temozolamide for newly diagnosed and recurrent glioblastoma multiforme (GBM)
Presenter: Azhar Rashid
Session: Poster display session
Resources:
Abstract